Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively.

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF).

WATERLOO, Ontario, March 20, 2025 (GLOBE NEWSWIRE) -- Teledyne DALSA, a Teledyne Technologies [NYSE: TDY] company and global leader in machine vision, announces the new Tetra™ line scan camera family. Designed for a wide range of machine vision applications, Tetra leverages Teledyne's latest multiline CMOS image sensor technology and builds on the success of the original Linea™ series of high-value line scan cameras.

Meta Platforms is attractively priced after a significant price drop, trading below its 50 and 200-day moving averages, making it a compelling buy. Meta demonstrates strong fundamentals with robust revenue growth, improving profitability, and a dominant position in social media, supported by its Family of Apps. The company's strategic pivot toward AI, including the high adoption of Llama and Ray-Ban Meta AI glasses, offers promising new growth avenues.

BURLINGTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that Marion Harris, a long-time Ford Motor Company executive, has been appointed to serve as an independent, non-executive director, effective April 1, 2025.

+130% Increase Since January 1, 2025. Unveils Multi-Tier Revenue Drivers Leveraging a 12-Person Sales Team, DAX Partnership, and AI Marketing and Tesla Partnership to Convert to Paid Subscribers.

NO-HEADQUARTERS/REDWOOD CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- PubMatic, an independent technology company delivering digital advertising's supply chain of the future, today announces the success and impact of its Connect platform in driving incremental revenue and efficiency for publishers and advertisers through curated programmatic advertising deals.

PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (NCT06072612) and recommended …

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB: EVFM) for one of Evofem's FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate).

NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership.

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois.

Fans can enter creative mode ahead of the film's release with a new, limited-time meal and Happy Meal, both of which include collectibles, gaming exclusives & more CHICAGO , March 20, 2025 /PRNewswire/ -- From crafting pixel-perfect replicas of our Golden Arches and world-famous menu items, to stacking block upon block into full-on restaurants, fans have been building their love for McDonald's into Minecraft for years. Now, inspired by their imagination – and the global big screen adventure, A Minecraft Movie, debuting in theaters April 4 – we're bringing the game's cinematic world to McDonald's.

Spring Black Friday Set to Run April 3-16 ATLANTA , March 20, 2025 /PRNewswire/ -- Today is the first official day of spring, but most homeowners and renters agree that spring begins when they start their first home project (64%), according to a new survey conducted by Reputation Leaders for The Home Depot. The survey revealed that spring cleaning marks the start of the season in most households.

More than 80% of the wishes currently waiting to be granted involve travel PHOENIX , March 20, 2025 /PRNewswire/ -- Make-A-Wish is excited to announce the renewal of its partnership with Chase, expanding its support to help grant travel wishes for children battling critical illnesses. This renewed commitment will see Chase contributing $3 million, with a combination of Chase Ultimate Rewards® points and cash.

Fourth Quarter Comparable Sales Declined (3.0)% : a +190 Basis Point Improvement vs. Third Quarter 2024 Fourth Quarter Diluted GAAP EPS of $1.89 : Above the Midpoint of Updated Guidance Provided Company Announces Launch of Jordan Brand in 145 Stores and Online Beginning in Late April Quarterly Dividend Increased by 18% Per Share KATY, Texas, March 20, 2025 (GLOBE NEWSWIRE) -- Academy Sports and Outdoors, Inc. (Nasdaq: ASO) ("Academy" or the "Company") today announced its financial results for the fourth quarter and fiscal year ended February 1, 2025.

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week's earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial.

BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE's management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025.

BEIJING , March 20, 2025 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced it will host a conference call to discuss fourth quarter and full year 2024 results on Friday, March 28, 2025, at 8:00 a.m. EST. The earnings release and related investor deck will be available prior to the event in the "Quarterly Results" section under "Financials", while the live webcast will be available in the "Events" section under the "News & Events" header on the investor relations website ir.chechegroup.com.

-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 -- -- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 -- -- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 -- BOSTON , March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused …